2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoic acid | 845616-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoic acid
• 英文别名: 2-cyclopropylmethoxy-5-methanesulfonyl-benzoic acid；2-(cyclopropylmethoxy)-5-methylsulfonylbenzoic acid
• CAS: 845616-03-7
• 化学式: C₁₂H₁₄O₅S
• 分子量: 270.306
• InChiKey: UHIUKQYOJQBHDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.92h， 生成 5-[2-(cyclopropylmethoxy)-5-methanesulfonylbenzoyl]-2-(2-fluorophenyl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazole
  参考文献：
  名称：

  Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties

  摘要：

  We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the identification of a novel series of pyrrolo[3,4-c]pyrazoles amides (21-50) with good in vitro potency. Subsequent optimization of physicochemical and in vitro ADME properties produced several compounds with promising pharmacokinetic profiles. In vivo inhibition of GlyT1 was demonstrated for select compounds within this series by measuring the elevation of glycine in the cerebro-spinal fluid (CSF) of rats after a single oral dose of 10 mg/kg. Ultimately, an optimized lead, compound 46, demonstrated in vivo efficacy in a rat novel object recognition (NOR) assay after oral dosing at 0.1, 1, and 3 mg/kg.

  DOI：

  10.1021/acs.jmedchem.8b00372
• 作为产物：
  描述：

  methyl 2-(cyclopropylmethoxy)-5-methylsulfonylbenzoate 在 sodium hydroxide 、 水 作用下， 生成 2-(cyclopropylmethoxy)-5-(methylsulfonyl)benzoic acid
  参考文献：
  名称：

  Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors

  摘要：

  Screening of the Roche compound library led to the identification of the benzoylpiperazine 7 as a structurally novel GlyT1 inhibitor. The SAR which was developed in this series resulted in the discovery of highly potent compounds displaying excellent selectivity against the GlyT2 isoform, drug-like properties, and in vivo efficacy after oral administration. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.086

文献信息

• Heterocyclic-substituted phenyl methanones
  申请人：Jolidon Synese

  公开号：US20060178381A1

  公开（公告）日：2006-08-10

  The present invention relates to compounds of formula I wherein R 1 , R 2 , and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.

  本发明涉及式I的化合物 其中 R 1 ， R 2 ，并在规范中定义，并且其药学上可接受的酸盐。
• Substituted phenyl methanones
  申请人：Jolidon Synese

  公开号：US20060167023A1

  公开（公告）日：2006-07-27

  The present invention relates to compounds of general formula IA or IB wherein X 1 and X 2 are each independently N or C—R″ and R 1 , R 2 ,R 3 , R 4 , R 5 , and R 6 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used for the treatment of diseases related to the glycine transporter inhibitor, such as schizophrenia and Alzheimer's disease.

  本发明涉及一般式IA或IB的化合物，其中X1和X2分别独立地为N或C—R″，R1、R2、R3、R4、R5和R6如规范中所定义，并且其药学上可接受的酸盐。这些化合物可用于治疗与甘氨酸转运体抑制剂相关的疾病，如精神分裂症和阿尔茨海默病。
• Benzoyl-tetrahydropiperidine derivatives
  申请人：Jolidon Synese

  公开号：US20060148797A1

  公开（公告）日：2006-07-06

  The present invention relates to compounds of formula I wherein R 1 , R 2 , and Ar; are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts thereof and methods for the treatment of neurological and neuropsychiatric disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

  本发明涉及具有如下式I的化合物，其中R1、R2和Ar如规范中定义的。该发明还提供其药用可接受的酸盐及用于治疗神经和神经精神障碍的方法，例如精神分裂症、认知障碍和阿尔茨海默病。
• Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups
  申请人：Jolidon Synese

  公开号：US20060128712A1

  公开（公告）日：2006-06-15

  The present invention relates to compounds of the general formula I wherein R 1 is the group and R 2 , R′, R″, R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 1′ , X 2 , and N are as defined in the specification. Compounds of the invention are useful for the treatment of neurological and neuropsychiatric disorders.

  本发明涉及一般式I的化合物，其中R1是该基团，而R2、R′、R″、R3、R4、R5、R6、R7、X1、X1′、X2和N如规范中所定义。本发明的化合物对治疗神经和神经精神疾病有用。
• Monocyclic substituted phenyl methanones
  申请人：Jolidon Synese

  公开号：US20060167009A1

  公开（公告）日：2006-07-27

  The present invention relates to compounds of formula I wherein R 1 , R 2 , X 1 , and X 2 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. Such compounds are inhibitors of the glycine transporter 1 (GlyT-1) and can be used in the treatment of schizophrenia, cognitive impairment, and Alzheimer's disease.

  本发明涉及公式I的化合物，其中R1，R2，X1和X2的定义如规范中所述，以及其药学上可接受的酸盐。这些化合物是甘氨酸转运体1（GlyT-1）的抑制剂，可用于治疗精神分裂症、认知障碍和阿尔茨海默病。